Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trialMillie Long, James Fon, Thomas Baker et al.|The Lancet. Gastroenterology & hepatology|2026Cited by 6
S717 The Effect of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results at Week 12 by Prior Inadequate Response or Intolerance to Advanced TherapyDavid T. Rubin, Julián Panés, Jessica R. Allegretti et al.|The American Journal of Gastroenterology|2022Cited by 0